Abstract 432P
Background
Cyclin-dependent kinase 4/6 inhibitor (CDK4/6i) combined with endocrine therapy has been approved as first-line treatment for hormone receptor-positive(HR+) advanced breast cancer (ABC). A challenge is finding biomarkers to identify patients who respond to treatment with CDK4/6i.
Methods
We identified all patients in treatment with CDK4/6i for ABC in our centre. Restrospectively, we analyzed the values of Ki 67 and progesterone receptor(PR) detected by inmunohistochemistry and their impact on CDK4/6i duration and progression-free survival(PFS). PFS was evaluated by Kaplan Meier method and survival curves were compared using the longrank test. Results were considered statistically significant with a p value <0’05. Analyses were realized with SPSS.
Results
Between January 2018 and January 2023, 210 patients received CDK4/6i treatment at our institution, 68’6% (144) received palbociclib, 24’3%(51) ribociclib and 7’1%(15) abemaciclib. The media age was 52 years (36-91). The median follow up time was 21 months (range 1-69 months). Ki 67 and PR expression were analyzed both as continuos and dichotomized variables and PR was classified as positive or negative. In the total population, patients with Ki67 >30% had significant shorter CDK4/6i treatment duration versus Ki 67<30% (16’80 months vs not reached, p=0’04). In regard to PR expression, we observed patients with PR positive had longer CDK4/6i treatment duration compared with PR negative (17’54 vs 7’55 months, p=0’027). Also, if we analyzed PFS, we observed patients PR positive had longer PFS versus PR negative (45’50 months vs 17’71 months, p=0’02), we recorded PFS as the duration from the beginning of treatment to disease progression or death, whichever happened first.
Conclusions
In clinical practical, there is a high individual variability in clinical response in patient with CDK4/6i treatment. Actually, there are not biomarkers that predict which patients respond to treatment. In this study, we investigated the impact of Ki67 and PR values on CD4/6i treatment in HR-positive ABC patients. Also, we revealed that PFS seemed to be negatively influenced by elevated Ki 67 values (>30%) and negative PR expression. We have to corroborate these data in prospective studies.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Hospital Universitario Reina Sofia.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
349P - The influence of diabetes on taxane-induced neurotoxicity and quality of life in breast cancer patients
Presenter: Erika Cimbro
Session: Poster session 03
350P - Quality of life data on sexual relations in early breast cancer patients
Presenter: María Garrido
Session: Poster session 03
351TiP - EORTC BCG 1984 – NOBLE: Noeoadjuvant olaparib and durvalumab for patients with BRCA-associated triple-negative breast cancer
Presenter: Emanuel Buhrer
Session: Poster session 03
352TiP - Neoadjuvant chemo-immunotherapy plus/minus fasting-like approach in stage II-III triple-negative breast cancer patients: The phase II randomized BREAKFAST-2 trial
Presenter: Claudio Vernieri
Session: Poster session 03
355P - Reduction of anthracycline use with a combined imaging and pathology prediction model in the neoadjuvant I-SPY2 trial
Presenter: Angela DeMichele
Session: Poster session 03
356P - Prognostic value of the residual cancer burden after neoadjuvant chemotherapy for invasive lobular breast cancer: An international pooled cohort study
Presenter: Soumya Gottipati
Session: Poster session 03
357P - Prediction of pathologic response to neoadjuvant chemotherapy (NAC) using diffuse optical breast scanner (DOB-Scan) in patients with locally advanced breast cancer (LABC)
Presenter: Phuong Thao Nguyen
Session: Poster session 03
358P - Major adverse cardiovascular event outcomes of adjuvant taxane + anthracycline versus taxane-based chemotherapy in older adults with triple-negative breast cancer: A SEER-Medicare study
Presenter: Savannah Roy
Session: Poster session 03